Publications

Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Blood Stream Infections: SENTRY Antimicrobial Surveillance Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Patients with Blood Stream Infections (BSI) in North America (NA): SENTRY Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Extreme Variations in Susceptibility (S) of P. aeruginosa (PSA) Among Hospitals in North America (NA), Latin America (LA), Europe (EU) and the Asia-Pacific (AP): Report from the SENTRY Antimicrobial Surveillance Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Frequency of Occurrence of Bacterial Pathogens in Bacteremic Infections and Antimicrobial Susceptibility From the SENTRY Surveillance Programme in Europe 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Regional Variations and Trends in Antimicrobial Resistance Among E. faecalis (EF) and E. faecium (EFM) in the Global SENTRY Antimicrobial Surveillance Program (1997-2000), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Pediatric and Adult Patients with Blood Stream Infections in North America: SENTRY 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Pediatric and Adult Patients with Blood Stream Infections in North America: SENTRY 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against H. influenzae and M. catarrhalis, Including In Vitro Test Development Comparisons, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Staphylococci and Enterococci, Including In Vitro Test Development and Comparisons, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Streptococci, Including In Vitro Test Comparisons and Development, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Streptococci, Including In Vitro Test Comparisons and Development, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Activity Of Gatifloxacin Against S. pneumoniae, H. influenzae, and M. catarrhalis Before (1997-99) and During (2000) the Clinical Release in North America (NA): A SENTRY Antimicrobial Surveillance Program Report, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 Against 2,681 Recent Clinical Isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the US, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Activity and Spectrum of BMS 284756 Tested Against 3546 Strains of Ciprofloxacin-Resistant Gram-Positive Cocci, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Neisseria gonorrhoeae, Including In Vitro Test Comparisons and Development BMS284756 MIC ( m m g/ ml), presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Activity Of BMS284756, A Novel Desfluoroquinolone, Against Streptococci, Including Initial In Vitro Test Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Geographic Variations in BMS 284756 Activity Against Pathogens Associated with Skin and Soft Tissue Infections: Report from the SENTRY Antimicrobial Surveillance Program (2000), presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Geographic Variations in BMS284756 Activity and Spectrum Tested Against Common Respiratory Tract Pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2000), presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Tested Against Enteric Bacilli, Including In Vitro Test Comparisons and Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) AgainstThree Groups of Non-fermentative Gram-negative Bacilli, Including In Vitro Test Comparisons And Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity Of BMS 284756 (T-3811; A Desfluoroquinolone) Trend Against Anaerobes and Selected Fastidious Species (Campylobacter, Helicobacter, Legionella), Including Limited In Vitro Methods Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Ability of the Latin America Centers to Detect Antimicrobial Resistance Patterns: Experience of SENTRY Surveillance Antimicrobial Program 1997-1999, presented at 101st annual American Society for Microbiology General Meeting (ASM), May 20-24, 2001, Orlando, Florida

Importance of Non-Fermentative Gram-Negative Bacilli (NFB) Causing Serious Infections: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997-1999), presented at 101st annual American Society for Microbiology General Meeting (ASM), May 20-24, 2001, Orlando, Florida

Accuracy of the Broth Microdilution and Etest Methods for Detecting Chloramphenicol (CM) Acetyltransferase-Producing Strains of S. pneumoniae (SPN) Including World-Wide Geographic Variations in the Prevalence of Resistance Observed in the SENTRY Program, presented at 101st annual American Society for Microbiology General Meeting (ASM), May 20-24, 2001, Orlando, Florida

Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: More evidence for a class concept. by Jones RN published in J. Clin. Microbiol. 2001; 39 (10): 3810-3811

Cefditoren in vitro activity and spectrum: A review of international studies using reference methods. by Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC and Fuchs PC published in Diagn. Microbiol. Infect. Dis. 2001; 41 (1-2): 1-14

Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different! by Jones RN, Beach ML and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 41 (3): 161-163

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) closing summary. Hamburg, Germany, 10 May 2001. by Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 197-198

Determining the value of antimicrobial surveillance programs. by Jones RN and Masterton R published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 171-175

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. by Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M and Jones RN. published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S81-S93

Surveillance of antibiotic resistance in European ICUs. by Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R and Wolff M published in J. Hosp. Infect. 2001; 48 (3): 161-176

BMS284756 potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (2000). Abstr P40. by Gordon KA, Pfaller MA, Jones RN, Sader HS, Biedenbach DJ, Beach ML and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 1): S26-S27

Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: Report from the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Fusco J, Biedenbach DJ, Pfaller MA and Jones RN. published in Antimicrob. Agents Chemother. 2001; 45 (12): 3599-3600

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. by Gales AC, Reis AO and Jones RN published in J. Clin. Microbiol. 2001; 39 (1): 183-190

Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: Results from the MYSTIC Programme. by Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 125-127

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). by Gales A, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2001; 45 (5): 1463-1466

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). by Gales AC, Jones RN, Forward KR, Linares J, Sader HS and Verhoef J published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S104-S113

Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. by Gales AC, Jones RN, Turnidge J, Rennie R and Ramphal R published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S146-S155

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. by Fix AM, Pfaller MA, Biedenbach DJ, Beach ML and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (2): 141-145

Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates. by Erwin ME, Fix AM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 129-132

Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. by Diekema DJ, Beach ML, Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2001; 7 (3): 152-157

Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997- 1999. by Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN and Beach M published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S114-S132

Oxazolidinone antibiotics. by Diekema DJ and Jones RN published in Lancet 2001; 358 (9297): 1975-1982

Accuracy of broth microdilution and Etest methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999). by Deshpande LM, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 267-269

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria. by Deshpande LM, Gales AC and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (1): 29-35

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods. by Deshpande L, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (5): 437-440

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 257-260

In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (1): 49-53

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. by Biedenbach DJ, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 245-250

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 40 (4): 173-177